October 10, 2013

In re: Ariad Pharmaceuticals, Inc. Securities Litigation

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


  1. May 10, 2018

    3 Firms Win 25% Fee Approval For $3.5M Ariad Deal

    A Massachusetts federal judge on Thursday afternoon gave his approval to a $3.5 million class action settlement between a group of investors and Takeda Pharmaceutical Co. unit Ariad Pharmaceuticals Inc., including a 25 percent cut plus expenses for the three firms that revived the suit and secured the deal.

4 other articles on this case. View all »


Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!